Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its position in shares of AmerisourceBergen Corp. (NYSE:ABC) by 7.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 47,637 shares of the company’s stock after purchasing an additional 3,209 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in AmerisourceBergen were worth $4,062,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Profund Advisors LLC increased its stake in shares of AmerisourceBergen by 20.4% in the 4th quarter. Profund Advisors LLC now owns 5,326 shares of the company’s stock valued at $489,000 after acquiring an additional 904 shares during the last quarter. Jefferies Group LLC bought a new stake in shares of AmerisourceBergen in the 4th quarter valued at about $541,000. Two Sigma Advisers LP bought a new stake in shares of AmerisourceBergen in the 4th quarter valued at about $1,887,000. Raymond James & Associates increased its stake in shares of AmerisourceBergen by 11.6% in the 4th quarter. Raymond James & Associates now owns 124,584 shares of the company’s stock valued at $11,440,000 after acquiring an additional 12,928 shares during the last quarter. Finally, Elkfork Partners LLC bought a new stake in shares of AmerisourceBergen in the 4th quarter valued at about $4,373,000. 66.11% of the stock is owned by hedge funds and other institutional investors.

In related news, CFO Tim G. Guttman sold 11,367 shares of the stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $84.23, for a total transaction of $957,442.41. Following the completion of the sale, the chief financial officer now directly owns 56,472 shares of the company’s stock, valued at approximately $4,756,636.56. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 21,350 shares of the stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $84.63, for a total value of $1,806,850.50. Following the sale, the chairman now directly owns 287,925 shares of the company’s stock, valued at $24,367,092.75. The disclosure for this sale can be found here. Over the last three months, insiders have sold 112,631 shares of company stock valued at $9,604,033. 27.30% of the stock is owned by company insiders.

AmerisourceBergen opened at $86.33 on Thursday, according to Marketbeat.com. AmerisourceBergen Corp. has a 52-week low of $71.90 and a 52-week high of $106.27. The company has a debt-to-equity ratio of 1.38, a current ratio of 0.94 and a quick ratio of 0.48. The company has a market cap of $19.08 billion, a P/E ratio of 13.89, a price-to-earnings-growth ratio of 1.35 and a beta of 1.04.

AmerisourceBergen (NYSE:ABC) last posted its earnings results on Wednesday, May 2nd. The company reported $1.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.13. AmerisourceBergen had a return on equity of 51.04% and a net margin of 0.57%. The business had revenue of $41.03 billion during the quarter, compared to analysts’ expectations of $40.56 billion. During the same period in the prior year, the business earned $1.77 EPS. AmerisourceBergen’s revenue for the quarter was up 10.5% compared to the same quarter last year. sell-side analysts expect that AmerisourceBergen Corp. will post 6.47 earnings per share for the current year.

A number of analysts have recently commented on the company. ValuEngine raised AmerisourceBergen from a “sell” rating to a “hold” rating in a research note on Saturday, June 16th. Zacks Investment Research cut AmerisourceBergen from a “hold” rating to a “sell” rating in a research note on Thursday, April 12th. Morgan Stanley lowered their price target on AmerisourceBergen from $97.00 to $88.00 and set an “equal weight” rating for the company in a research note on Tuesday, July 3rd. Barclays lowered their price target on AmerisourceBergen from $104.00 to $95.00 and set an “equal weight” rating for the company in a research note on Tuesday, March 27th. Finally, Royal Bank of Canada set a $101.00 price target on AmerisourceBergen and gave the company a “hold” rating in a research note on Monday, April 2nd. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $102.13.

AmerisourceBergen Company Profile

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.

Read More: Book Value Of Equity Per Share – BVPS Explained

Want to see what other hedge funds are holding ABC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AmerisourceBergen Corp. (NYSE:ABC).

Institutional Ownership by Quarter for AmerisourceBergen (NYSE:ABC)

Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.